Introduction: Standards of Medical Care in Diabetes—2022
Open accessAbstract
The need for a consensus report arises when clinicians, scientists, regulators
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The ADA and KDIGO each follow structured processes to assess data and develop rigorous, evidence-based guidelines for adults with diabetes and CKD.
“The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) each follow structured processes to assess these data and develop rigorous, evidence-based guidelines for adults with diabetes and CKD (1,2).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Standards of Care section (p. 1) describes the ADA’s structured literature search and annual guideline updates, while Grading of Scientific Evidence (p. 2) describes its evidence-rating system. These passages support the claim about the ADA’s process, but this paper does not establish the corresponding claim about KDIGO or specifically describe guideline development for adults with both diabetes and CKD. (LLM, conf=0.82)
Experimental — accuracy not yet measuredBoth the ADA and KDIGO guidelines recommend individualized and balanced diets that are high in vegetables, fruits, and whole grains but low in refined carbohydrates and sugar-sweetened beverages.
“The ADA and KDIGO guidelines both recommend individualized and balanced diets that are high in vegetables, fruits, and whole grains but are low in refined carbohydrates and sugar-sweetened beverages (1,2).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) says ADA recommendations should be adjusted for individual preferences, and Grading of Scientific Evidence (p. 2) emphasizes individual circumstances. This supports individualization of care, but this introduction does not give the claimed dietary recommendations or discuss KDIGO guidelines. (LLM, conf=0.78)
Experimental — accuracy not yet measuredBoth the 2022 ADA Standards of Care and KDIGO 2022 guideline recommend comprehensive care in which pharmacotherapy that is proven to improve clinical kidney and cardiovascular outcomes is layered upon a foundation of healthy lifestyle approaches.
“Both recommend comprehensive care in which pharmacotherapy that is proven to improve clinical kidney and cardiovascular outcomes is layered upon a foundation of healthy lifestyle approaches.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) describes multifactorial risk reduction and says the ADA Standards include therapeutic actions intended to improve health outcomes. The Grading of Scientific Evidence section (p. 2) also discusses multiple risk-factor control. This copy does not specify pharmacotherapy layered on healthy lifestyle approaches or identify improved kidney and cardiovascular outcomes; it cannot establish what KDIGO recommends. (LLM, conf=0.83)
Experimental — accuracy not yet measuredThe 2022 ADA Standards of Care and KDIGO 2022 guideline are aligned on issues of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management.
“The 2022 ADA Standards of Care and KDIGO 2022 guideline are aligned on issues of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management (1,2).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) identifies this work as the 2022 ADA Standards of Care and says its recommendations include screening, diagnosis, treatment, and general treatment goals. It does not discuss the KDIGO 2022 guideline or establish alignment on CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, or pharmacologic management. (LLM, conf=0.83)
Experimental — accuracy not yet measuredBoth the ADA and KDIGO emphasize the importance of comprehensive, holistic, patient-centered medical care to improve overall patient outcomes.
“Therefore, both the ADA (1) and KDIGO (2) emphasize the importance of comprehensive, holistic, patient-centered medical care to improve overall patient outcomes.”
Multimorbidity is common in patients with diabetes and CKD.
“Multimorbidity is common in patients with diabetes and CKD, who are at high risk of CKD progression, cardiovascular events, and premature mortality.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) says diabetes care should account for comorbidities, and Grading of Scientific Evidence (p. 2) mentions comorbid and coexisting diseases. Neither addresses whether multimorbidity is common specifically among patients with both diabetes and CKD. Searches for that claim and for CKD with coexisting conditions found no supporting passage in our copy. (LLM, conf=0.74)
Experimental — accuracy not yet measuredBoth the ADA and KDIGO guidelines recommend a low-sodium diet (KDIGO <2,000 mg/day, ADA 1,500 to <2,300 mg/day).
“Both guidelines also recommend a low-sodium diet (KDIGO <2,000 mg/day, ADA 1,500 to <2,300 mg/day), largely to control BP and reduce cardiovascular risk.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) describes the ADA Standards of Care generally, but gives no sodium-intake recommendation. A search of our copy for the stated sodium ranges and for sodium in relation to blood pressure or cardiovascular risk found no relevant passage. This introduction therefore cannot verify the attributed dietary guidance. (LLM, conf=0.75)
Experimental — accuracy not yet measuredThe ADA and KDIGO guidelines advise moderate to intense/vigorous physical activity with a cumulative duration of ≥150 min/week and avoidance of sedentary activity.
“The ADA and KDIGO guidelines also advise moderate to intense/vigorous physical activity with a cumulative duration of ≥150 min/week and avoidance of sedentary activity (1,2).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [1]
The Introduction (p. 1) describes the ADA Standards of Care generally, but does not state a physical-activity recommendation. Searches of our copy for 150 minutes per week, moderate-to-vigorous activity, and avoidance of sedentary activity found no passage addressing those specifics. (LLM, conf=0.78)
Experimental — accuracy not yet measuredGLP-1 receptor agonists are an effective treatment for glycaemic control and weight reduction in people with type 2 diabetes and have a good safety and tolerability profile, including in those with CKD.
“GLP-1RAs are an effective treatment for glycaemic control and weight reduction in people with T2D and have a good safety and tolerability profile (generally transient gastrointestinal adverse events being most common), including in those with CKD [3,4].”
GLP-1 receptor agonists improve glycaemic control and lower body weight in people with type 2 diabetes.
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grant, R. W., & Kirkman, M. S. (2014) · Diabetes Care · doi:10.2337/dc14-2142 · Cited by 191 · see citing works
Zhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0018 · Cited by 173 · see citing works
Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel, K. R., Ali, M. K., Zhou, X., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Gregg, E. W., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0017 · Cited by 168 · see citing works
Medical Management of Type 1 Diabetes
Low Wang, C. C., & Shah, A. C. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580406307 · Cited by 46 · see citing works
Medical Management of Type 2 Diabetes
Meneghini, L. F. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · see citing works
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · see citing works
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · see citing works
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919 · see citing works
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · see citing works
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98 · see citing works
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104 · see citing works
Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022) · Clinical Epidemiology · doi:10.2147/clep.s391819 · Cited by 93 · see citing works
Silver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15113 · Cited by 94 · see citing works
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47 · see citing works
Alva, M. L., Chakkalakal, R. J., Moin, T., & Galaviz, K. I. (2022) · Health Affairs · doi:10.1377/hlthaff.2022.00259 · Cited by 33 · see citing works
Dening, J., Mohebbi, M., Abbott, G., George, E. S., Ball, K., & Islam, S. M. S. (2023) · Nutrition & Diabetes · doi:10.1038/s41387-023-00240-8 · Cited by 31 · see citing works
Kristensen, F. P. B., Sanchez-Lastra, M. A., Dalene, K. E., del Pozo Cruz, B., Ried-Larsen, M., Thomsen, R. W., Ding, D., Ekelund, U., & Tarp, J. (2023) · Diabetes Care · doi:10.2337/dc23-0937 · Cited by 29 · see citing works
Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1514 · Cited by 18 · see citing works
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S1-S2
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200310486
- Cited by
- 807
- References
- 5
- Citations by year
- 2026: 54 · 2025: 120 · 2024: 114 · 2023: 200 · 2022: 165 · 2021: 40 · 2020: 65 · 2019: 36 · 2018: 8 · 2017: 2 · 2016: 1
- FWCI
- 97.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, health care standards, diabetes management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
